49

Olson, Stephen

0102M82681

50

Olson, Stephen

0102M82701

51

Olson, Stephen

0111M12742

52 53

Olson, Stephen Olson, Stephen

0202M17441 0206M26802

A Randomized, Open-Label, Rater-Blinded Assessment of Optimal Treatment Change Strategy to Risperidone for Patients Intolerant of Olanzapine (Risperidone Rescue Study) Janssen Pharmaceutica Protocol RIS-USA-250 A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of Sustained-release Formulation Quetiapine Fumarate (Seroquel TM) and Placebo in the Treatment of Patients with Schizophrenia AstraZeneca Protocol 5077IL/0041 Comparative Effectiveness of Antipsychotic Medications in Patients with Schizophrenia-Clinical Antipsychotic Trials of Intervention Effectiveness - The CATIE Study Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison - The Cafe Study Diagnostic Assessment Core (DAC) for Studies in Schizophrenia and Related Disorders

3/20/2001

5/22/2002

4/9/2001

12/27/2002

2/11/2002

7/22/2005

4/22/2002 7/31/2002

8/8/2005 7/11/2008

54

Olson, Stephen

0309M52650 Protocol HGU-MC-HGLM A Randomized, Double-Blind, Placebo-Controlled and RisperdoneReferenced, Parallel-Group Efficacy and Safety of Two Fixed Doses of 0309M52651 Bifeprunox in the Treatment of Schizophrenia (Protocol S1543001) An Open-Label, Flexible-Dose, Long-Term Safety and Efficacy Study of Bifeprunox in the Treatment of Schizophrenia, Protocol S1543002 (Extension 0309M52653 of Protocol S1543001) A Multicenter, Open-label, Flexible-dose, Parallel-group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL) and Risperdone (RISPERDAL) in the Long-term Treatment of Patients with 0310M53142 Schizophrenia or Schizoaffective Disorder Protocol 5077IL/0089 An Double-Blind Randomized Study Comparing Intramuscular Olanzapine Depot with Placebo in the Treatment of Patients with Schizophrenia, Protocol 0407M61923 F1D-MC-HGJZ(b) An Open-Label Study of Intramuscular Olanzapine Depot in Patients with 0407M61924 Schizophrenia or Schizoaffective Disorder, Protocol F1D-MC-HGKB(b) A Randomized, Placebo-Controlled, Double-Blind Trial of Asenapine in the 0509M73986 Prevention of Relapse after Long-Term Treatment of Schizophrenia A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Subjects 0602M81590 who Completed Protocol A7501013 (Protocol A7501014) A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing the Safety and Efficacy of Asenapine with Olanzapine in Stable Subjects with Predominant, Persistent Negative Symptoms of Schizophrenia 0602M81591 (Protocol A7501013) A Multicenter, Double-Blind, Randomized, Parallel Group, Active-Controlled Tolerability and Safety Study of MK-3756(SM-13496/Lurasidone) in Clinically 0603M83470 Stable Schizophrenia Outpatients

12/18/2003

6/28/2006

55

Olson, Stephen

3/18/2004

8/23/2005

56

Olson, Stephen

3/18/2004

8/22/2008

57

Olson, Stephen

2/25/2004

11/13/2008

58

Olson, Stephen

9/21/2004

7/11/2005

59

Olson, Stephen

9/21/2004

7/11/2005

60

Olson, Stephen

1/5/2006

11/20/2008

61

Olson, Stephen

7/31/2006

1/27/2008

62

Olson, Stephen

6/29/2006

1/27/2008

63

Olson, Stephen

7/14/2006

1/4/2007

64 65 66

Olson, Stephen Olson, Stephen Olson, Stephen

67

Olson, Stephen

68

Olson, Stephen

Effectiveness of Switching from Injectable Conventional Antipsychotic 0603M84169 Medications to Injectable Risperidone(Switch or Stay) Effectiveness of Switching From Antipsychotic Polypharmacy to 0606M87346 Monotherapy (Stay or Switch Study) A Randomized, Double-Blind Study of Olanzapine Versus Aripiprazole in the 0606M88386 Treatment of Schizophrenia (F1D-MC-HGLB(a)) A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Aripiprazole Used as Dual Therapy in the Treatment of Patients with Chronic Stable Schizophrenia or Schizoaffective Disorder Demonstrating an Inadequate Response to Quetiapine or Risperidone Monotherapy (CN 0607M90126 138397) A Randomized, Parallel Group, Multiple Dose, 6-Week Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Asenapine in Elderly Subjects 0608M90546 with Psychosis (Protocol A 7501021) Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to Aripiprazole versus Continued Treatment with Olanzapine, Quetiapine, or Risperidone Comparison of Antipsychotics for Metabolic 0609M93066 Problems (the CAMP study) A Multi-Center, Open-Label, Parallel-Group, Randomized, Flexible Dose Study to Evaluate the Safety and Tolerability of Switching from Existing Atypical Antipsychotics to Bifeprunox in Subjects with Schizophrenia or 0610M95446 Schizoaffective Disorder. Protocol S1543020 A 24-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of Oral Doses of AVE 1625 5, 10, and 30 mg and Placebo on Top of an Established Treatment Regimen of either Olanzapine, Risperidone or Quetiapine Monotherapy in the Treatment of 0701M00343 Cognitive Impairment in Schizophrenia Validation of the Reasons for Antipsychotic Discontinuation/Continuation 0703M04621 Questionnaire (RAD-Q) and Interview (RAD-I)

7/19/2006 7/19/2006 9/15/2006

1/15/2010 1/15/2010 4/23/2007

9/21/2006

2/5/2008

3/6/2007

8/1/2008

69

Olson, Stephen

11/28/2006

7/14/2011

70

Olson, Stephen

1/23/2007

5/8/2008

71

Olson, Stephen

3/12/2007

12/4/2009

72

Olson, Stephen

5/3/2007

3/11/2009

73

Olson, Stephen

0710M19001

74

Olson, Stephen

0710M19084

75 76 77 78

Olson, Stephen Olson, Stephen Olson, Stephen Olson, Stephen

0809M45541 0809M46541

A Multi-Center Randomized, Placebo-Controlled, Double-Blind, ParallelGroup, Phase IIb Proof of Concept Study with 3 Oral Dose Groups of AZD3480 During 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia 1/10/2008 'A Randomized, Multicenter, Double-Blind, Parallel Group Study to Compare the Effects of the Bifeprunox and Quetiapine on Weight Changes in Stable Schizphrenia Patients' Protocol S1543021 11/7/2007 A Phase 2 6-Week Double Blind, Placebo-Controlled, Multicenter Trial of Varenicline Tartrate (CP-526,555) For Cognitive Impairment in Subjects With Schizophrenia. Protocol Number A3051100 9/18/2008 Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia 11/11/2008 11/10/2008 7/1/2009

11/20/2008

5/12/2008

3/9/2009 8/10/2010 8/10/2010 6/2/2010

0809M46901 Comparison of Optimal Antipsychotic Treatments for Schizophrenia (COATS) 0905M65703 Cognitive Remediation in the Schizophrenia Trials Network (CRiSTN) A Prospective , Randomized Active-controlled, Rater-blinded Study of the Prevention of Relapse Comparing Paliperidone Palmitate with Oral Risperidone in Adults with Recently-Diagnosed Schizophrenia Who Are at High Risk of Relapse Study Number: R092670-SCH-3004 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients with Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone A Multicenter, Open-label Study to Assess Hospitalization Rates in Adult Subjects with Schizophrenia Treated Prospectively for 6 Months with Aripiprazole IM Depot Compared with 6-month Retrospective Treatment with Oral Antipschotics in a Naturalistic Community Setting in North America (ARRIVE).

79

Olson, Stephen

0910M73857

11/12/2009

3/9/2010

80

Olson, Stephen

1004M80519

7/6/2010

10/12/2011

81

Olson, Stephen

1011M93235

3/24/2011

8/29/2013

82

Olson, Stephen

1202M10381

7/23/2012

4/8/2013

83

Olson, Stephen

MOSAIC: The Management of Schizophrenia in Clinical Practice: A Prospective, Non-Interventional Registry of Diverse Patients with Schizophrenia Across the Disease Spectrum in Usual Care Settings: Course of 1303M29344 Disease, Treatments, and Burden of Illness

3/28/2013